• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correspondence to "Locoregional therapy in de novo metastatic breast cancer: Systematic review and meta-analysis, written by Reinhorn D et al. In The Breast Journal 58 (2021) 173-181".

作者信息

Soran Atilla, Ozbas Serdar, Dogan Lutfi, Isik Arda, Sezgin Efe

机构信息

Magee-Womens Hospital Comprehensive Breast Program, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Private, Breast and Endocrine Surgeon, Ankara, Turkey.

出版信息

Breast. 2021 Dec;60:304-305. doi: 10.1016/j.breast.2021.10.002. Epub 2021 Oct 8.

DOI:10.1016/j.breast.2021.10.002
PMID:34654601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8714499/
Abstract
摘要

相似文献

1
Correspondence to "Locoregional therapy in de novo metastatic breast cancer: Systematic review and meta-analysis, written by Reinhorn D et al. In The Breast Journal 58 (2021) 173-181".致信《局部区域治疗初治转移性乳腺癌：系统评价与荟萃分析》，作者为莱因霍恩·D等人。发表于《乳腺杂志》58卷（2021年）第173 - 181页。
Breast. 2021 Dec;60:304-305. doi: 10.1016/j.breast.2021.10.002. Epub 2021 Oct 8.
2
Clinicopathologic factors associated with de novo metastatic breast cancer.与新发转移性乳腺癌相关的临床病理因素。
Pathol Res Pract. 2016 Dec;212(12):1167-1173. doi: 10.1016/j.prp.2016.09.007. Epub 2016 Sep 22.
3
Reply to: "Impact of Primary-Site Local Therapy in Patients with De Novo Metastatic Breast Cancer," by Makris, Eleftherios et al.回复：Makris, Eleftherios等人所著的《原发部位局部治疗对初诊转移性乳腺癌患者的影响》
Ann Surg Oncol. 2023 Feb;30(2):1072-1073. doi: 10.1245/s10434-022-12873-7. Epub 2022 Dec 3.
4
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.接受一线曲妥珠单抗为基础治疗的新诊断 IV 期或复发性 HER2 阳性转移性乳腺癌患者的治疗模式和临床结局：一项多中心回顾性队列研究。
Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11.
5
Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.细胞周期蛋白依赖性激酶 4 和 6 抑制剂与激素受体阳性转移性乳腺癌患者生存的关联：系统评价和荟萃分析。
JAMA Netw Open. 2020 Oct 1;3(10):e2020312. doi: 10.1001/jamanetworkopen.2020.20312.
6
The Difference in Prognostic Outcomes Between Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer.激素受体阳性、HER2阴性的IV期与复发性转移性乳腺癌患者预后结果的差异。
In Vivo. 2018 Mar-Apr;32(2):353-358. doi: 10.21873/invivo.11245.
7
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.局部区域治疗与转移性乳腺癌中肿瘤原发灶不治疗的比较：一项开放标签随机对照试验。
Lancet Oncol. 2015 Oct;16(13):1380-8. doi: 10.1016/S1470-2045(15)00135-7. Epub 2015 Sep 9.
8
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.曲妥珠单抗治疗新诊断的Ⅳ期人表皮生长因子受体 2（HER2）阳性乳腺癌的长期生存。
Oncologist. 2019 Mar;24(3):313-318. doi: 10.1634/theoncologist.2018-0213. Epub 2018 Aug 23.
9
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.曲妥珠单抗为基础的治疗用于 HER2 阳性初治或复发的 IV 期乳腺癌女性的临床结局。
Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005. Epub 2013 Nov 7.
10
De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.乳腺癌中的新发转移：按分子亚型分层的发生和总生存情况。
Clin Exp Metastasis. 2017 Dec;34(8):457-465. doi: 10.1007/s10585-017-9871-9. Epub 2017 Dec 29.

引用本文的文献

1
Nomogram for predicting the risk and prognosis of lung metastasis of four subtypes of breast cancer: A population-based study from SEER.预测四种亚型乳腺癌肺转移风险和预后的列线图：一项基于监测、流行病学和最终结果（SEER）数据库的人群研究
Cancer Pathog Ther. 2024 Aug 3;3(2):154-162. doi: 10.1016/j.cpt.2024.08.001. eCollection 2025 Mar.

本文引用的文献

1
Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial.原发肿瘤切除术联合全身治疗新辅助治疗 IV 期乳腺癌患者：10 年随访；MF07-01 号方案随机临床试验。
J Am Coll Surg. 2021 Dec;233(6):742-751.e5. doi: 10.1016/j.jamcollsurg.2021.08.686. Epub 2021 Sep 13.
2
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis.局部区域治疗新诊断转移性乳腺癌：系统评价和荟萃分析。
Breast. 2021 Aug;58:173-181. doi: 10.1016/j.breast.2021.05.003.
3
Clinical Evidence for Locoregional Surgery of the Primary Tumor in Patients with De Novo Stage IV Breast Cancer.初诊 IV 期乳腺癌患者局部肿瘤切除术的临床证据。
Ann Surg Oncol. 2021 Sep;28(9):5059-5070. doi: 10.1245/s10434-021-09650-3. Epub 2021 Feb 3.
4
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study.仅存在骨转移的初诊 IV 期乳腺癌患者行初始手术治疗的效果（方案 BOMET MF 14-01）：一项多中心、前瞻性登记研究。
Ann Surg Oncol. 2021 Sep;28(9):5048-5057. doi: 10.1245/s10434-021-09621-8. Epub 2021 Feb 2.
5
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.随机对照试验比较初诊 IV 期乳腺癌中肿瘤切除术与无手术治疗的疗效：MF07-01 方案。
Ann Surg Oncol. 2018 Oct;25(11):3141-3149. doi: 10.1245/s10434-018-6494-6. Epub 2018 May 17.